| 2026-03-02 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18:07 |
國內首個「AI+RNA」小分子創新藥完成首例患者給藥，晶泰科技與ReviR共研「一藥多治」管線RTX-117瞄準千億級神經退行性疾病市場
深圳2026年3月2日 /美通社/ -- 2026年3月2日，晶泰科技（2228.HK）孵化企業ReviR溪礫科技（下稱「ReviR」）宣佈，其小分子藥物管線RTX-117完成首例受試者給藥。這一里程碑進展標誌著由晶泰科技與ReviR 合作發現的國內首個「AI+RNA」小分子藥物RTX-117正式進入臨床開發階段，作為國內相關領域首個進入臨床的 1 類創新藥管線，有望為腓骨肌萎縮症（CMT）、白質消融性白質腦病（VWM）等神經系統疾病患者提供顛覆性的治療方案，覆蓋超 100 億美元的全球治療市場，晶泰科技有權參與該管線的銷售分成及後續授權收益分成。這是又一款晶泰科技參與研發並獲取後續商業化權益分成的首創新藥進入臨床，晶泰科技通過廣泛參與並賦能高價值領域新藥管線的創新突破與臨床轉化，正持續强化其作為AI製藥龍頭企業的領先優勢與商業化價值。
RTX-117 是晶泰科技與 ReviR一系列深度合作中首個進入臨床的候選藥物，結合晶泰科技的 AI+機器人藥物研發平台與 ReviR對RNA 生物學的深入理解，由雙方合作發現並設計優化，是國內唯一一款從分子層面干預疾病病理通路的小分子候選藥物。其臨床前數據及臨床獲批速度均超出雙方預期，展現了晶泰科技 AI 藥物研發平台的高效性與ReviR強大的管線推進能力。本次首例人體給藥的完成標誌著臨床試驗的正式啟動，將進一步驗證其藥物特徵及相關影響。本次臨床試驗為隨機、雙盲、安慰劑對照的單次、多次給藥劑量遞增研究以及食物影響研究，旨在評估RTX-117在健康受試者中的安全性、耐受性、藥代動力學（PK）與藥效動力學（PD）特徵，以及食物影響。 目前，RTX-117已獲得腓骨肌萎縮症（CMT）的中美臨床試驗「雙報雙批」及白質消融性白質腦病（VWM）的國內臨床批件，成為國內首款在這兩項適應症中獲批臨床的藥物管線。CMT和VWM均為致死/致殘性罕見病，多數患者在年少發病並持續進展，全球尚無有效療法，存在巨大未被滿足的臨床需求。RTX-117作為該領域具備First-in-class潛力及前沿進展的創新藥，有望填補巨大的治療市場空白，撬動全球超100億美元的治療市場。其「一藥多治」策略還可通過同一分子在不同適應症中的相互驗證，顯著提升該管線開發的成功率。 RTX-117 通過抑制異常激活的ISR通路，恢復 mRNA 的正常翻譯，達到從分子根源上治療疾病的效果。該通路不僅對VWM 和 CMT 的治療至關重要，還被認為與漸凍症（ALS）、帕金森病（PD）、阿爾茨海默病（AD）以及腦損傷等多種神經系統疾病密切相關。隨著其I期臨床實驗的有序推進，未來，RTX-117有望進一步拓展至更多適應症，潛在覆蓋人群預計超5000萬。 在RTX-117 的成功研發中，晶泰科技的AI藥物研發平台展現了精準的藥物設計能力，與ReviR的VoyageR AI平台及其對底層疾病機制的深刻洞見結合，有望實現更高效的RNA翻譯調控及創新靶點開發，為「AI+RNA」神經退行性疾病藥物研發提供可複製的成功實踐。 ReviR 聯合創始人、董事長李陽博士表示：很高興我們能順利完成 RTX-117 的首例人體給藥，這是新藥研發中的關鍵里程碑，也是 ReviR 團隊專業性、研發路徑優越性和臨床方案科學性的體現，感謝臨床研究中心和患者群體及相關組織的支持，期待臨床試驗的進一步推進能給患者群體帶來新的治療希望。 關於ReviR Therapeutics（溪礫科技） ReviR Therapeutics 是一家處於臨床階段的全球生物技術公司，致力於結合 AI 技術與 RNA 生物學，開發高特異性、有效且安全的疾病修飾療法。憑借自研平台 VoyageR 深厚的技術積澱，ReviR 已在神經系統疾病和自身免疫領域佈局多條創新藥管線。其主要候選小分子藥物 RTX-117 當前正推進針對腓骨肌萎縮症（CMT）/白質消融性白質腦病（VWM）的臨床試驗，並持續拓展新適應症。 關於晶泰科技 晶泰科技（"XtalPi Holdings Limited"，股份簡稱：晶泰控股，XTALPI，股票代碼：2228.HK）由三位麻省理工學院的物理學家於 2015 年創立，是一個基於量子物理、以人工智能賦能和機器人驅動的創新型研發平台。公司採用基於量子物理的第一性原理計算、人工智能、高性能雲計算以及可擴展及標準化的機器人自動化相結合的方式，為製藥及材料科學（包括農業技術、能源及新型化學品以及化妝品）等產業的全球和國內公司提供藥物及材料科學研發解決方案及服務。 關於RTX-117 RTX-117 是ReviR溪礫科技自主研發的1 類創新藥，由晶泰科技（2228.HK）的 AI+機器人研發平台賦能其發現與設計優化，為全球首個利用 AI 開發的腓骨肌萎縮症（CMT）/白質消融性白質腦病（VWM）的小分子療法，也是國內唯一具備該雙適應症臨床批件的創新管線，以抑制整合應激反應（Integrated Stress Response, ISR）為核心機制，通過激活 eIF2B 恢復 mRNA 的正常翻譯，重建蛋白表達穩態，改善神經肌肉功能，以達到治療效果。在高效推進 RTX-117 針對 CMT 臨床研究的同時，ReviR 已正式開啟針對 VWM 等拓展適應症的系統性佈局，旨在通過同一底層機制覆蓋更廣泛的神經系統臨床需求。 Information Provided by PR Newswire [Disclaimer]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 15:00 |
TCL Unveils Next-Generation NXTPAPER Technology on AMOLED, Redefining Visual Comfort and Mobile Display Excellence
BARCELONA, Spain, March 2, 2026 /PRNewswire/ -- At the 2026 Mobile World Congress (MWC), TCL announced a groundbreaking advancement in its proprietary NXTPAPER eye-care technology. For the first time, NXTPAPER's signature full-color electronic display technology will be integrated with AMOLED displays, marking a major leap forward in the mobile viewing experience. This significant advancement combines the unparalleled picture quality, rich, finely detailed visuals and exceptional brightness of AMOLED with TCL's industry-leading eye care display performance, delivering a display that is both exceptionally vibrant and remarkably gentle on the eyes during prolonged viewing. Through natural-light-like visual comfort and an extraordinary paper-like experience, this brings global users a truly unmatched level of visual comfort on smartphones, leading the industry into a new era of intuitive, visually comfortable mobile display technology. "As screen time continues to rise, from early messages to night scrolling, visual fatigue has become a shared modern experience. As the primary medium through which we perceive the world and access information, displays must not only deliver stunning image quality but also prioritize visual health." said Jefferson Li, General Manager of TCL Mobile Phone. "This new milestone in our NXTPAPER journey reflects TCL's unwavering commitment to human-centric innovation. By integrating NXTPAPER with AMOLED, we are addressing the market demand for displays that don't force users to choose between vivid visuals and eye comfort. This advancement brings us closer to our mission of creating a smartphone viewing experience that feels incredibly natural and comfortable while staying easy on the eyes even during prolonged use."
Visual Comfort Inspired by Natural Light At the heart of the advancement of NXTPAPER lies a simple yet powerful idea: screens should feel as natural to the eyes as natural light. Inspired by this principle, whether you're scrolling through social media on your morning commute, catching up on notifications under harsh office lighting, or enjoying a late-night reading session in bed, NXTPAPER delivers all-day long and all scenarios comfortable viewing experience through comprehensive multi-dimensional optimizations. Key Advancements
On a hardware level, major advancement comes from the upgraded Circular Polarizer Light (CPL) technology. The polarization rate has been elevated from 57% to 90% compared to the previous generation, reaching an industry-leading level and enabling light emission that more closely resembles the light emitting behavior of natural light. Harmful blue light has also been further reduced by another 15%, bringing it down to as low as 2.9%. To further align with natural viewing rhythms, the circadian screen comfort dynamically adjusts brightness and color temperature throughout the day, following the patterns of ambient daylight. In low-light environments, dim-light eye protection can adjust the brightness, which can be reduced to as low as 1 nit, creating a calm, night-friendly visual experience that minimizes disruption and supports long-term comfort. Optimized Paper-Like Experience with Industry First Anti-Glare Technology Building on TCL's signature paper-like display concept, this latest NXTPAPER display elevates digital viewing into a more immersive and refined experience. Eye fatigue is influenced not only by how a screen emits light, but also by how it reflects ambient light. NXTPAPER optimizes towards both directions to create a viewing experience that truly mirrors the comfort of paper—whether you're reading under a sunny window, working outdoors, or unwinding with a book before bed. Key Advancements
For the first time, an anti-glare (AG) technology will be implemented on AMOLED display in the smartphone industry, effectively reducing environmental glare while preserving clarity. By applying nano-matrix lithography technology, NXTPAPER minimizes ambient light reflections and glare, creating a viewing experience that closely resembles real paper. Whether you're reading outdoors on a bright sunny day or working near a window, the display remains crystal clear and comfortable, no more tilting your screen or searching for shade. Complementing the hardware innovation, the adaptive reading mode is also developed that automatically adjusts the background color based on surrounding light conditions, helping maintain consistently comfortable visuals across different environments. Together, these enhancements make this latest NXTPAPER display particularly suitable for long-form content consumption, seamlessly blending eye comfort with modern digital convenience. Exceptional True-to-Life Viewing Experience By integrating NXTPAPER with a cutting-edge AMOLED panel, TCL unlocks a new level of visual fidelity - advanced eye comfort and premium display quality without compromise. With professional-grade color accuracy of ΔE<1 and 100% P3 wide color gamut coverage, the display delivers true-to-life visuals that photographers, online shoppers, and movie lovers can trust. The peak brightness of 3200 nits enables users to navigate outdoors under bright sunlight. With a 120Hz refresh rate, users are able to enjoy smooth scrolling. This fusion ensures that while your eyes are soothed by NXTPAPER's advanced comfort technologies, you're simultaneously treated to a premium viewing experience that sets a new benchmark for mobile displays. Powered by TCL's End-to-End Display Strength This latest breakthrough is driven by TCL's vertically integrated display ecosystem, bringing together the expertise of TCL CSOT (China Star Optoelectronics Technology) and its global leadership across multiple display categories. From large screens to mobile displays, TCL's mastery of display technology enables innovations that span the entire product portfolio. As one of the leading global innovators in display technologies, TCL CSOT focused on promoting the development of next-generation display technologies such as Mini LED, Micro LED, OLED, and Inkjet Printing OLED to lead the future technology trend. This deep technical foundation ensures seamless integration of NXTPAPER and AMOLED display. TCL's leadership is validated by the market. According to shipment data from global research firm Omdia for 2024, TCL achieved Global TOP 1 rankings in Mini LED TV shipments, Google TV shipments, and 85-inch and larger TV shipments, reinforcing its position as a leading force in next-generation large-screen display technologies. This scale and expertise across big screens present unique insights into how consumers interact with displays in every aspect of their lives. Disclaimer Figures calculated in the release are based on stringent internal testing procedures. About TCL TCL Electronics (1070.HK) is a leading consumer electronics brand and leader in the global television industry. TCL now operates in more than 160 markets around the world. The company specializes in the research, development, and manufacturing of consumer electronics products ranging from TVs, audio, home appliances, mobile devices including mobile phones, tablets, smart connected devices, smart glasses, commercial displays, and more. Visit the TCL website at https://www.tcl.com. Media Contact:
Information Provided by PR Newswire [Disclaimer]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 15:00 |
TCL Unveils New TCL CrystalClip Open-Ear Earbuds, with Special Edition Featuring Crystals by Swarovski®
BARCELONA, Spain, March 2, 2026 /PRNewswire/ -- TCL today announces the TCL CrystalClip, its brand-new open-ear, clip-on earbuds designed for seamless integration into modern lifestyles, along with a standout special edition. Elevated with a detachable accessory adorned with crystals by Swarovski®, the special edition offers a unique blend of immersive audio and wearable elegance. Designed for Discerning Lifestyle Engineered for breathable, pressure-free comfort, TCL CrystalClip incorporates a titanium alloy arch bridge that ensures a secure, customized fit while remaining exceptionally lightweight, supporting extended wear without the intrusive "plugged-in" sensation. With up to 36 hours of battery life and quick charging capabilities, it is always ready for your next move. Premium Audio Meets Intelligent Features Intelligence is just a touch away. With intuitive touch controls, TCL CrystalClip also unlocks powerful simultaneous interpretation when paired with compatible TCL AI phones and apps, breaking language barriers for meetings, events, and travel scenarios. Special Edition: Sparkle Your Day with Radiant Crystals by Swarovski® The accessory embodies versatile sophistication. It can be worn with the earbuds or detached to add a personalized sparkle to any look—as a chic accent on a bag, hat, or lapel, or styled into hair as a refined detail. This adaptability empowers users to express their unique style, proving that technology can be a seamless and elegant part of daily life.
Price & Availability Disclaimer About TCL Media Contact Information Provided by PR Newswire [Disclaimer]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 13:48 |
全新旗艦機Xiaomi 17、Xiaomi 17 Ultra 及 Leica Leitzphone powered by Xiaomi 矚目登陸香港
承襲Leica影像精髓 締造旗艦手機影像新典範 香港2026年3月2日 /美通社/ -- 小米今日發佈其最新旗艦機型 Xiaomi 17 Series，展示公司在流動影像技術領域的最新突破。同時，小米今年將與Leica的合作關係迎來重大升級。雙方合作模式由高度成功的聯合研發框架，提升至全新的戰略共創模式，體現了更深度、更全面的點到點夥伴關係。
在此升級模式下孕育而生的 Xiaomi 17 Ultra 及 Leica Leitzphone powered by Xiaomi，為流動影像樹立了新標杆，將旗艦級影像表現、流線型機身以及耐用且符合人體工學的精巧設計融為一體。憑藉Leica逾百年的影像專業技術，Xiaomi 17 Series以領先業界的相片及影片拍攝能力為核心，呈獻完整的旗艦智能手機體驗。 Xiaomi 17 Series提供Xiaomi 17 Ultra和Xiaomi 17兩款全新智能手機，連同限量特別版Leica Leitzphone powered by Xiaomi將於3月2日中午12時在全線小米之家、小米之家專賣店、小米官網mi.com、香港各大運營商和零售商門市及網站同步接受預訂, 並享有以下優惠，而在3月6日起正式發售。
Xiaomi 17 Series ：Leica 佰年影像傳承 極致光影體驗 週末駕臨 4 大商場 開放時間：早上 11:00至晚上 9:00
雋永設計 搭配無可比擬的小米金剛緩震結構 作為迄今最纖薄、最輕巧的 Xiaomi Ultra 機型1，Xiaomi 17 Ultra 機身厚度僅 8.29mm²，重量低至 218.4g²，採用經精細打磨的全平面機身，配以極窄邊框、重新設計位置且更小巧低調的鏡頭Deco 裝飾件。提供白色、黑色或迷人的星空綠³ 三種顏色選擇，盡顯頂級裝置應有的高貴質感。除了驚艷外觀，小米金剛緩震結構更確保了機身堅固耐用，配備Xiaomi Shield Glass 3.0，抗摔性能較 Xiaomi 15 Ultra 提升 30%²，加上高強度玻璃纖維背板、鋁合金邊框以及 IP68⁶ 防塵防水等級，提供全面保護。 若追求更精緻的的影像與科技體驗，Xiaomi 17 搭載頂尖運算能力、先進影像功能及強勁電池的同時，機身厚度僅 8.06mm²，重量僅 191g²。提供綠色、粉紅色、藍色及黑色³ 等多款色彩選擇，配以重新設計的鏡頭Deco、大幅減少邊框過渡的弧度，以及僅 1.18mm² 的極窄邊框。Xiaomi 17 不僅外型時尚、大膽奪目，還堅固耐用，採用 6M42 鋁合金邊框、Xiaomi Shield Glass及擁有 IP68⁶ 認證，確保耐用可靠，讓用戶安心使用。
小米 X Leica ：極具遠見的影像合作 Xiaomi 17 Ultra 專為強大而多元的影像拍攝而設計，搭載小米首款 1 吋 LOFIC 主攝鏡感光元件，開創技術新境。Light Fusion 1050L 影像感光元件採用尖端電容技術，大幅提升全井電荷容量，實現新一代 HDR 表現。另一項關鍵突破是配備機械光學變焦的Leica 2 億像素 75–100mm 鏡頭。此長焦鏡頭依照Leica APO 光學認證打造，在整個變焦範圍內保持高影像質素，極致減少鬼影及色差；憑藉先進感光元件技術，可擴展至 400mm (17.2 倍) 等效焦距，實現出色的遠攝效果。除了先進的靜態攝影能力，Xiaomi 17 Ultra 更提供超動態影片攝錄，配備影院級錄製、色彩及防震功能，包括在主攝鏡及長焦鏡上支援高達 4K 120fps 的 Dolby Vision® 或 ACES Log 格式錄影。 與此同時，輕巧的Xiaomi 17 亦配備多功能的影像系統，核心為頂級的 Light Fusion 950 影像感光元件，尺寸為 1/1.31 吋，配備 2.4μm 四合一大像素，實現高達 13.5EV 的高動態範圍，在任何光線下都能呈現豐富逼真的影像。此系統輔以Leica 60mm 浮動長焦鏡頭，支援 60mm 人像拍攝、5 倍光學級變焦、精確的 10cm 微距拍攝及 20 倍 AI 超高倍變焦。自拍方面，全新 5,000 萬像素前置相機無論遠近對焦均有提升。影片攝錄功能同樣強大，支援 4K 60fps Dolby Vision® 及 4K 60fps Log 格式錄影，確保細節清晰、色彩一致及非凡穩定性，提升畫面清晰度並簡化工作流程，滿足專業級攝錄需求。 秉承Leica豐富的攝影傳統，Xiaomi 17 Ultra 領先業界的鏡頭系統可透過兩款升級版攝影配件進一步提升。全新的 Xiaomi 17 Ultra 輕薄攝影套裝設計更輕巧便攜，配備手帶、可自訂的兩段式快門按鍵、專用影片按鍵及 IP5412防護等級，設計靈感源自專業相機，並提供多種顏色選擇。對於攝影發燒友，Xiaomi 17 Ultra 專業攝影套裝則可將體驗提升至更高層次，配備向經典Leica機身致敬的高級防滑 PU 皮革手柄、內置 2000mAh (典型值) 電池、可拆卸的快門按鍵以實現個性化人體工學設計，以及獨特的快拍模式 UI，為專業拍攝提供全面掌控。 精英表現 極致性能 Xiaomi 17 Series配備革命性的小米澎湃電池，引入新一代電源技術，採用業界領先的 16% 矽含量，實現非凡能量密度與續航能力。Xiaomi 17 Ultra 配備高達 6000mAh (典型值) 的超大電池容量，支援 90W 有線極速充電及 50W 無線極速充電；而 Xiaomi 17 則配備更大的 6330mAh (典型值) 電池容量，支援 100W 有線極速充電及 50W 無線極速充電4。這些先進電池技術不僅助力系列保持纖薄輕巧的設計，更確保在快速供電下依然流暢運行，提供功能豐富的使用體驗。 精湛顯示技術 強調色彩、清晰度與效能 系列引入小米訂製 M10 顯示面板，提供更高亮度的同時提升效能。Xiaomi 17 Ultra 更首度採用小米 HyperRGB 技術，這是一種重新設計的 OLED 子像素排列方式，可增強清晰度並進一步優化電源使用，鞏固小米在銳利鮮明顯示屏方面的聲譽。
隆重推出限量特別版 Leica Leitzphone powered by Xiaomi Leica Leitzphone powered by Xiaomi 配備創新的Leica相機環，這是一個帶有滾花飾面的實體撥盤，握持手感媲美真正的變焦相機。手機同時引入Leica Essential模式，重現標誌性的Leica相機（包括Leica M9 及配備 MONOPAN 50 菲林的Leica M3）影像質素與攝影風格。 下載高清圖片按此 Xiaomi 17, Xiaomi 17 Ultra及 Leica Leitzphone powered by Xiaomi 規格
備注： 1. 此資訊更新於 2026 年 2 月。 關於小米集團 小米集團成立於2010年4月，2018年7月9日在香港交易所主板掛牌上市（1810.HK），是一家以智能手機、智能硬件和IoT平台為核心的消費電子及智能製造公司。 胸懷「和用戶交朋友，做用戶心中最酷的公司」的願景，小米致力於持續創新，不斷追求極致的產品服務體驗和公司運營效率，努力踐行「始終堅持做感動人心、價格厚道的好產品，讓全球每個人都能享受科技帶來的美好生活」的公司使命。 小米目前是全球領先的智能手機品牌之一，智能手機出貨量穩居全球前三。截至2024年9月全球月活躍用戶數（包括智能手機和平板產品）為6.86億。同時，小米已經建立起全球領先的消費級AIoT（人工智能和物聯網）平台，截至2024年9月30日，小米AIoT平台已連接的IoT設備（不包括智能手機、筆記本電腦及平板）數達到8.61億。2023年10月，小米宣佈最新戰略升級為「人車家全生態」，從個人設備到智能家居再到智能出行，以人為中心，致力於提供全面及更優質的互聯體驗。集團業務已進入全球逾100個國家和地區。2024年8月，小米集團連續六年進入《財富》「世界500強排行榜」（Fortune Global 500）。 小米集團目前為恒生指數、恒生中國企業指數、恒生科技指數及恒生神州50指數成份股。 更多關於小米集團的資訊，歡迎瀏覽https://www.mi.com/global/discover/newsroom。 #xiaomihk Information Provided by PR Newswire [Disclaimer]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 11:21 |
TENCENT Sets Release Date for Honor of Kings: World in Apr; Pre-registration Now Available on Apple iOS
TENCENT (00700.HK)'s multiplayer adventure game, Honor of Kings: World, has officially been scheduled for release in April, with pre-registration now open on Apple iOS. Information Provided by AAStocks Financial News [Disclaimer]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 11:21 |
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year
SHANGHAI, March 2, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in the S&P Global Sustainability Yearbook 2026 ("Yearbook") in recognition of its strong performance in the 2025 Corporate Sustainability Assessment (CSA). The company was ranked top in its industry and achieved a Top 1% S&P Global CSA Score, marking the fourth consecutive year that WuXi Biologics has received this highest level of distinction. The Yearbook aims to highlight individual companies — within a range of industries — that have demonstrated strong corporate sustainability performance, based on their S&P Global 2025 CSA Score. Out of the over 9,200 companies assessed in the 2025 CSA, only 848 companies, across 59 industries, were recognized as the top performers and selected for inclusion in Yearbook 2026. Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "Our strong performance in S&P Global's latest CSA and our inclusion in the Yearbook for the fourth consecutive year reflect WuXi Biologics' steadfast commitment to continuously enhancing our sustainability performance. We are a proven global leader in Green CRDMO, consistently delivering ESG excellence, enabling partners worldwide to fulfill their ESG commitments, and jointly working with all stakeholders to promote responsible practices throughout the entire value chain." As a participant of the United Nations Global Compact (UNGC) and the Pharmaceutical Supply Chain Initiative (PSCI), WuXi Biologics proactively advocates sustainability and has earned widespread recognitions for its efforts. The company was granted an MSCI AAA Rating; awarded an EcoVadis Platinum Medal; listed in the Dow Jones Sustainability Indices (DJSI); named to the CDP "A List" for Climate Change,Water Security, and Supplier Engagement Assessment; given the highest negligible-risk rating by Sustainalytics, and recognized as a Sustainalytics industry and regional ESG top-rated company for five consecutive years; selected as a Constituent of the FTSE4Good Index Series; listed in the Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating. About WuXi Biologics WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide. With over 12,000 skilled employees in China, the United States, Ireland, Germany, Singapore and Qatar, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing. WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com Contacts Media Information Provided by PR Newswire [Disclaimer]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 08:00 |
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
SAN FRANCISCO and SUZHOU, China, March 2, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces the non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, Jaypirca® (pirtobrutinib), has received approval by the National Medical Products Administration (NMPA) in China for a new indication for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) after at least one line of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor. Pirtobrutinib is a highly selective kinase inhibitor that utilizes a novel non-covalent binding mechanism to extend the benefit of targeting the BTK pathway in CLL/SLL patients previously treated with a covalent BTK inhibitor (ibrutinib, acalabrutinib, or zanubrutinib).[1],[2] Pirtobrutinib received approval from the U.S. FDA in January 2023 as a non‑covalent (reversible) BTK inhibitor. In October 2024, pirtobrutinib was approved in China as a monotherapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received at least two prior systemic therapies, including a Bruton's tyrosine kinase (BTK) inhibitor. The approval of this new indication is based on results from the international, multicenter, randomized, Phase 3 BRUIN CLL‑321 study. BRUIN CLL‑321 is the world's first randomized Phase 3 trial conducted in patients with CLL/SLL who had previously been treated with a covalent BTK inhibitor (cBTKi). The study enrolled a total of 238 patients and evaluated the efficacy and safety of pirtobrutinib monotherapy versus investigator's choice of IdelaR (idelalisib plus rituximab) or BR (bendamustine plus rituximab). The results demonstrated that pirtobrutinib significantly prolonged median progression‑free survival (PFS) compared with the investigator's choice regimen (14.0 months vs 8.7 months; hazard ratio [HR] = 0.54). In addition, the discontinuation rate due to treatment‑related adverse events was lower with pirtobrutinib (5.2% vs 21.1%), further supporting its efficacy and tolerability advantages in patients previously treated with a covalent BTK inhibitor.[3] Professor Lu-Gui Qiu, Principal Investigator of the BRUIN CLL‑321 study in China, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, stated, "BTK inhibitors have become the preferred first‑ or second‑line treatment for patients with CLL/SLL, yet some patients still experience disease progression and have a poor prognosis. Studies have shown that the median overall survival for patients after discontinuing a covalent BTK inhibitor is only about 22.7 months.[4] Therefore, there is an urgent clinical need for new treatment. As a next‑generation, non‑covalent and reversible BTK inhibitor, pirtobrutinib represents an important advancement for patients with relapsed or refractory CLL. The BRUIN CLL‑321 study demonstrated its therapeutic potential in CLL/SLL. We believe it will offer an important treatment option for patients with CLL/SLL in China and help meet the needs of long‑term disease management in the future." Dr. Li Wang, Lilly Corporate Senior Vice President, Head of Lilly China Drug Development & Medical Affairs Center, states, "The approval of pirtobrutinib for the CLL/SLL indication in China marks an important milestone in the treatment journey for Chinese CLL/SLL patients. It means that patients who continue to experience disease progression after covalent BTK inhibitor therapy can now gain timely access to this globally innovative treatment option. Supported by the efficacy and safety demonstrated in the BRUIN CLL‑321 study, we are pleased to offer a new therapeutic choice for CLL/SLL patient population with significant unmet medical needs in China. Looking ahead, Lilly will remain committed to accelerating the introduction of cutting‑edge therapies to help patients with hematologic malignancies in China achieve longer and better quality of survival. This is our enduring commitment to patients in China." Dr. Hui Zhou, Chief R&D Officer of Oncology in Innovent, stated, "Jaypirca (pirtobrutinib) is a next-generation, non-covalent (reversible) BTK inhibitor. It offers a novel treatment option for patients who have previously received covalent BTK inhibitor therapy. The approval in China for CLL/SLL represents a significant breakthrough in this field, which ensures that CLL/SLL patients in China have timely access to this global therapeutic innovation. We will fully leverage Innovent's leading brand presence and commercialization capabilities in oncology, to accelerate the accessibility of this innovative therapy, thereby benefiting more cancer patients in need." About BRUIN CLL-321 About Jaypirca (pirtobrutinib) In China, pirtobrutinib was developed by Eli Lilly and Company and is commercialized in mainland China by Innovent Biologics. About Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma About Innovent Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.
Forward-Looking Statements These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions. Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. References
Information Provided by PR Newswire [Disclaimer]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 2026-03-01 | |
|---|---|
| 14:45 |
XPENG Announces Vehicle Delivery Results for February 2026
GUANGZHOU, China, March 1, 2026 /PRNewswire/ -- XPeng Inc. ("XPENG" or the "Company," NYSE: XPEV and HKEX: 9868), a leading global AI mobility technology company, today announced its vehicle delivery results for February 2026. XPENG delivered a total of 15,256 vehicles in February. Also in February, XPENG began global deliveries of the new XPENG P7+, with the initial shipment bound for 18 countries. This milestone marks a significant step in bringing the vehicle's intelligent, spacious driving experience to young families worldwide. XPENG will also host a media experience event on March 2, 2026 in Guangzhou, where it will unveil its 2nd Gen VLA ahead of its official rollout in later March. About XPENG XPENG is a leading Chinese Smart EV company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers. Its mission is to become a smart technology company trusted and loved by users worldwide. In order to optimize its customers' mobility experience, XPENG develops in-house its full-stack advanced driver-assistance system technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. XPENG is headquartered in Guangzhou, China, with main offices in Beijing, Shanghai, Shenzhen, Silicon Valley and San Diego. The Company's Smart EVs are mainly manufactured at its plants in Zhaoqing and Guangzhou, Guangdong province. For more information, please visit https://www.xpeng.com/. Safe Harbor Statement This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Statements that are not historical facts, including statements about XPENG's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: XPENG's goal and strategies; XPENG's expansion plans; XPENG's future business development, financial condition and results of operations; the trends in, and size of, China's EV market; XPENG's expectations regarding demand for, and market acceptance of, its products and services; XPENG's expectations regarding its relationships with customers, suppliers, third-party service providers, strategic partners and other stakeholders; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in XPENG's filings with the United States Securities and Exchange Commission. All information provided in this announcement is as of the date of this announcement, and XPENG does not undertake any obligation to update any forward-looking statement, except as required under applicable law. Contacts: For Investor Enquiries: IR Department Jenny Cai For Media Enquiries: PR Department Information Provided by PR Newswire [Disclaimer]
|
| 2026-02-28 | |
|---|---|
| 14:02 |
MWC Barcelona 2026: YOFC to Unveil Hollow-Core Fibre (HCF) Solution, Advancing Optical Connectivity in the Era of AI
AI x Fibre: the company will highlight next-generation ultra-low latency optical communication technology, strengthening global AI infrastructure. BARCELONA, Spain, Feb. 28, 2026 /PRNewswire/ -- Yangtze Optical Fibre and Cable (YOFC) will showcase its latest innovative optical connectivity solutions for the AI era at MWC Barcelona 2026, taking place from March 2 to 5. Under the theme "AI x Fibre – Leading an Intelligent Future," the company will also host a dedicated launch event for its hollow-core fibre (HCF) solutions on March 4 at one of the world's largest and most influential connectivity events. As AI is rapidly reshaping global industries and societal operations, high-speed, low-latency, and highly reliable optical connectivity is becoming essential infrastructure for an intelligent world. As a key transmission technology supporting next-generation AI computing networks, HCF will take centre stage of YOFC's exhibition at booth 5A30. "Artificial intelligence is profoundly reshaping the global industrial landscape, placing unprecedented demands on ultra‑high‑speed, ultra‑low‑latency optical connectivity. As a premier global platform for mobile communications and digital technology, MWC provides a vital window to showcase cutting‑edge innovations and deepen international collaboration," remarked Zhuang Dan, Executive Director and President of YOFC. "We believe that advanced optical connectivity not only drives the efficient flow of computing power and data but also contributes to the development of the digital society, connecting us to a more inclusive and sustainable future. YOFC looks forward to working with global industry partners to co‑create a smarter, greener, and more efficient future of optical connectivity." Centring on "AI X Fibre," YOFC's exhibition at MWC Barcelona 2026 will especially spotlight five key technological highlights, demonstrating how optical fibre technology serves as the core backbone of global AI computing networks:
As a flagship innovation on display, YOFC's HCF represents the forefront of next-generation optical transmission technology. Offering significant advantages over traditional fibre including lower latency, higher transmission efficiency, and enhanced signal quality, it provides critical infrastructure for ultra-high-speed data transmission and AI computing networks. Further details will be unveiled at the launch event during MWC. As the world accelerates into the AI era, YOFC reinforced its commitment and unveiled the "AI-2030" strategy in 2025, positioning itself as a global leader in AI optical connectivity infrastructure. Built on its three core preform technologies—PCVD, VAD, and OVD—the company has developed a comprehensive "Superior Fibre" portfolio that includes G.654.E fibre, multi-core fibre, and hollow-core fibre (HFC), designed to meet the most demanding transmission needs. With over a decade of global expansion, YOFC now operates eight production facilities across six countries, serving more than 100 markets worldwide. Through active participation in international standard-setting and cross-industry collaboration, YOFC continues to drive digital and intelligent transformation on a global scale, making high-speed, reliable optical connectivity a driving force behind the advancement of digital society—supporting a smarter, more connected, and more inclusive digital future. Global industry partners, customers and media are invited to join YOFC at booth 5A30 at MWC Barcelona 2026 from March 2 to 5. The press conference for HCF launch will take place from 10 a.m. to 12 p.m. on March 4 at T6, Hall 8.0. For more information, please visit https://en.yofc.com/ Information Provided by PR Newswire [Disclaimer]
|
| 2026-02-27 | |
|---|---|
| 20:21 |
Zoomlion Opens 2026 With US$1.2 Billion in Global Equipment Shipments
More than 15,000 units delivered to customers in over 40 international markets CHANGSHA, China, Feb. 27, 2026 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion" or "the Company"; 1157.HK) announced a solid opening to 2026, with large-scale equipment deliveries across multiple international markets. From four major manufacturing hubs within Zoomlion Smart Industrial City, high-end, intelligent, and low-emissions equipment was shipped to customers worldwide, totaling more than 15,000 units with a combined value of approximately 8.5 billion yuan (approx. US$1.2 billion). Since the beginning of the year, Zoomlion's construction crane division has delivered more than 1,500 units valued at over 2.4 billion yuan (approx. US$350 million). The portfolio included the world's largest-capacity 4,000-ton all-terrain crane. Concrete machinery was also shipped to customers globally. A significant portion of this equipment is bound for 23 countries, including established markets in Germany, Australia, and the United Arab Emirates. In the earthmoving and mining segment, Zoomlion's integrated fleet solution—featuring high-performance hundred-ton-class mining excavators paired with battery-electric mining trucks—was a key component of the overall delivery volume. Over 3,700 units of earthmoving and mining machinery, valued at around 2.3 billion yuan (approx. US$335 million), were shipped from the Zoomlion Smart Industrial City Earthmoving Machinery Park, as well as facilities in Weinan and Quantang. Zoomlion delivered more than 4,000 units of aerial work platforms to over 40 countries and regions. The high-volume output was led by the 82-meter straight-boom aerial work platform, currently the tallest in its class. Outside Zoomlion Smart Industrial City, additional equipment was dispatched from Zoomlion's Changde Tower Crane Smart Factory and its Jiangyin production facility, where flagship and high-demand models were supplied to global customers. International orders accounted for more than 80% of the total order value during this period. These orders are destined for more than 40 countries and regions, including Italy, Hungary, the United States, Australia, Singapore, Turkey, Saudi Arabia, the United Arab Emirates, Colombia, Tanzania, Côte d'Ivoire, and Morocco. The Company's agricultural machinery, foundation construction machinery, emergency equipment, advanced materials, and other business divisions also completed international deliveries during the same period. Looking ahead, Zoomlion remains focused on product innovation and expanding its international footprint. The Company will continue to support customers worldwide with advanced, intelligent, and lower-emissions equipment and integrated solutions.
Information Provided by PR Newswire [Disclaimer]
|
